newsfilter
← Latest News
Business Wire·

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat granted Breakthrough Therapy and Orphan Drug Designations for cholestatic pruritus